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Abstract
Background: Although aged garlic extract (AGE) shares some active components with fresh garlic and in spite of
its palatability and milder side effects, the anti-diabetic and related anti-oxidant properties of AGE have not been
investigated extensively, and the reported findings are inconsistent.
This study investigated the anti-diabetic effects of 3 incremental doses of AGE in streptozotocin (STZ)-induced
diabetic rats (fasting blood sugar > 20 mM).
Method: Diabetic rats were divided into a control diabetic group (CD) and AGE-treated diabetic group (AGE-D).
The AGE-D was divided into 3 groups and accordingly treated with AGE i.p. at 100, 300 and 600 mg/kg daily for
8 weeks. A control normal group (CN) was also included for reference.
Results: Compared to the CN group, the CD group showed significant loss of body weight (over 50 %); and
decreased serum insulin concentration (10 fold) and total anti-oxidant level and catalase activity (45–70 %) in
serum, kidney and liver. Conversely, the CD rats had an elevated blood glucose (nearly 4 fold), serum cholesterol
(nearly 2 fold) and triglycerides (>2 fold), erythrocyte glycated hemoglobin (GHb, 3 fold) and kidney and liver
lipid peroxidation (MDA levels). Treatment with AGE positively reversed the diabetic changes in the targeted
parameters to levels significantly lower than those measured in the CD group and the degrees of attenuation
were almost dose dependent especially with the two higher doses.
Conclusion: AGE exhibits a dose-dependent ameliorative action on indicators of diabetes in STZ-induced
diabetic rats.
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Background
Fresh garlic (Allium sativum L.), a widely used condi-
ment and spice, is well known for its health-promoting
properties as reported in numerous human and animal
studies [1–14]. Garlic’s health-promoting properties,
which are of interest and fall within its antidiabetic
potentials, are: hyperinsulinemia, hypoglycemia, hypo-
cholesterolemia, hypotriglyceridemia and anti-glycation
and anti-lipid peroxidation actions, in addition to pro-
moting total anti-oxidant level and catalase activity. In
spite of having these valuable ameliorative actions,
fresh garlic consumption is, unfortunately, flawed by
the manifestation of unpleasant side effects which sig-
nificantly deter from its intake as a medicinal supple-
ment. Amongst others, these include unpleasant and
irritable gastrointestinal symptoms plus strong repellent
breath and body odor; side effects which result from
garlic oil soluble sulfur-containing compounds. An-
other deterrent to the use of fresh garlic is its form and
preparation, in addition to the inconsistency in the dose
of ingested active ingredients.
Aged garlic extract (AGE), produced by storing sliced
and macerated fresh garlic at room temperature for 20
months, is odorless and upon ingestion causes minimal
gastrointestinal irritability and socially unacceptable prop-
erties. These preferable attributes of AGE seem to result
from the aging process which reduces the oil-soluble
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odorous sulfur compounds and enhances the content of
water-soluble compounds [15]. AGE is also available
over the counter in a form suitable and ready for intake
with a known dose concentration. What is also interest-
ing about AGE is that it contains many of the bioactive
compounds found in fresh garlic including the water-
soluble allyl amino acid derivatives, stable lipid-soluble
allyl sulfides, flavonoids and saponins, and most im-
portantly and to a large extent, S-allylcysteine (SAC)
and S-allylmercaptocysteine (SAMC) [15, 16].
In vitro and in vivo studies on AGE have demonstrated
potent anti-thrombotic [17] and anti-oxidant [18] activ-
ities. In relation to the anti-thrombotic activity, AGE and
its constituents have been shown to inhibit ADP-induced
platelet aggregation in a dose dependent manner [19]. In-
hibition of platelet aggregation by AGE has been reported
to involve multiple mechanisms including changes in
intra-platelet [Ca+2], increase in intracellular cAMP and
reduction in the interaction of fibrinogen with the
CPIIb/IIIa receptor [19, 20]. In relation to anti-oxidant
properties, several studies have demonstrated that
AGE and its components have potent anti-oxidant ac-
tivity [14]. This activity is suggested to be the result of
scavenging free radicals and enhancing the cellular
anti-oxidant systems [18–21]. Furthermore, in animal
models, AGE has been shown to lower oxidative stress
(OS) by increasing endogenous anti-oxidant enzymes,
such as catalase and glutathione peroxidase (GPx), [22]
and lowering pro-oxidant enzymes such as xanthine
oxidase and NADPH oxidase [23]. AGE can also re-
duce the formation of superoxide and lipid peroxida-
tion and thus alleviate OS [24].
Diabetes mellitus (DM), an increasingly prevalent med-
ical condition, is characterized by hyperglycemia, dyslipid-
emia and OS. Clinical and experimental studies have
shown that diabetic hyperglycemia is a major source of
OS, and that increased generation of free radicals plays a
significant role in the pathogenesis and complications of
DM [25–28]. Urate and vitamin C, major contributors to
serum anti-oxidant activity, have shown to be significantly
reduced in both insulin-dependent DM and non-insulin-
dependent DM [29]. The basic mechanisms by which
chronic hyperglycemia promote increased OS have been
suggested to include glucose auto-oxidation, formation of
advanced glycation end-products (AGEs) and increased
activity of the sorbitol pathway [28–30].
During the last 20 years, many studies have investi-
gated the anti-diabetic potential of fresh garlic. Our
group and others have shown that raw garlic extract is
active in reducing hyperglycemia and alleviating many
diabetic indicators, such as dyslipidemia and OS in both
animal models and humans [10, 13, 31–35]. However,
few studies have examined the effects of AGE in diabetes
and those reports have described variable effects of AGE
on the classical indicators of DM. For example, Shiju
and coworkers [36] reported that treating streptozotocin
(STZ)-induced diabetic rats with 500 mg/kg of AGE for
12 weeks resulted in no change in blood glucose al-
though hemoglobin glycation (GHb) was clearly reduced.
In contrast, Balamash et al. [37] observed that treating
type 2 DM patients with 3000 mg of AGE daily for 3
months did not affect blood glucose, GHb or the serum
lipid profile in these patients, although lipid peroxida-
tion, an indicator of OS, was reduced.
Based on its acceptable palatability and milder side
effects, content of potent bioactive components and
conflicting reported effects in DM, the present study
was carried out to assess the anti-diabetic potential of
AGE by conducting an 8-week daily intraperitoneal (IP)
three incremental dose–response study in STZ-induced
diabetic rats. The doses investigated were selected based
on a pilot study. In addition to examining the effect of
AGE on the general indicators of diabetes, such as serum
insulin and glucose, erythrocyte GHb, food and water in-
take, urine output in addition to body weight changes, this
study also looked at the indicators of OS and dyslipidemia
to further delineate the scope of the anti-diabetic activity
of this garlic preparation.
Methods
Chemicals and kits
AGE (Kyolic AGE) was purchased as a liquid suspension
(Wakunaga, USA) containing 240 mg AGE/ml. All analysis
kits were purchased from the different sources as indicated
in their respective usage in this section.
Treatment of rats
Healthy 3 month old male Sprague–Dawley rats (150–180
g BW) maintained on standard rodent diet and tap water
ad libitum were used in the study. The rats were kept
under standard ambient conditions (23 ± 2 °C, 12 h light,
12 h darkness).
Diabetes was induced in 60 rats by a single IP injection
of STZ, 60 mg/kg in 0.5 ml of 0.01 M sodium citrate
buffer, pH 4.5. After 5 days, blood glucose was quanti-
tated after overnight fasting in a drop of tail-blood under
mild diethyl ether sedation using One-Touch Ultra-Easy
Glucometer (LifeScan, UK).
Diabetic rats (blood sugar level > 20 mM) were divided
into four groups (each, n = 12–16): Control diabetic
(CD) group injected IP daily with normal saline (NS);
low-dose AGE-diabetic (AGE100-D) group injected IP
daily with 100 mg AGE /kg; medium dose AGE-diabetic
(AGE300-D) group injected IP daily with 300 mg AGE/
kg; high dose AGE-diabetic (AGE600-D) group injected
IP daily with 600 mg AGE/kg. A group of control nor-
mal rats (CN) that received NS was included as a
reference.
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The use of rats was in full compliance with the Guide
for the Care and Use of Laboratory Animals [38] and all
experimental protocols were approved by the Animal
Care and Use Committee at Faculty of Science–Kuwait
University.
Measurements, tissue preparation and biochemical assays
The body weight of the rats in all groups was recorded
before the start of the study and weekly during the ex-
perimental period. Twenty-four h water and food intake
were measured weekly and 24 h urine output was mea-
sured in each treatment group at 8 weeks by housing
the rats in metabolic cages.
After 8 weeks, the rats were sacrificed after overnight
fast under Sodium Pentobarbitone (10 mg/kg, May &
Baker, England). The blood was collected by cardiac punc-
ture into two separate tubes for serum and red blood cell
(RBC) preparation. For serum, 3 ml of blood was collected
in a tube and allowed to clot for 30 min at room
temperature. The tubes were centrifuged at 1000 × g for
15 min and the serum was separated, and stored as 0.5 ml
aliquots in Eppendorf tubes at −80 °C for later analysis.
For RBCs, 1 ml of whole blood was collected in a separate
glass tube containing 0.2 ml of 3.8 % sodium citrate as an
anticoagulant and mixed well. The tubes were centrifuged
at 1000 × g for 10 min and the plasma and buffy coat were
carefully removed from the cells. RBCs was mixed well
and analyzed for GHb on the same day.
Immediately after sacrifice, the liver and kidneys of
each rat were collected separately. The capsule of each
kidney was removed and the tissues were washed with
buffer, blotted with filter paper and stored at −40 °C for
later analysis. One gram of kidney or liver tissue was
diced and mixed with 3 ml Tris–HCl (0.05 M, pH = 7.6).
The mixture was homogenized, allowed to stand on ice
for a few minutes and then centrifuged for 15 min at 8000
× g at 4 °C. The supernatant was stored in small aliquots
at −40 °C for later analysis.
Glucose levels in whole blood were determined after
overnight fasting at 2, 4, 8 weeks as described above.
Total water-soluble antioxidants were determined by
the method of Rice-Evans and coworkers as modified
by Drobiova et al. [31] based on inhibition of the oxida-
tion of 2, 2 -azinobis-(3-ethylbenzothiazoline-6-sulfonic
acid) (ABTS). Serum insulin was determined by ELISA
using kits supplied by SPIbio (France). Total serum
cholesterol and triglycerides were determined spectro-
photometrically using test kits from Randox (USA).
Serum GHb was determined by an affinity chromatography
method using analysis kits from Helena Laboratories
(USA). Serum catalase was determined spectrophotome-
trycally by the method of Aebi [39]. Serum superoxide dis-
mutase (SOD) was determined spectophotometrically by a
coupled assay using a kit supplied by Cayman Chemical
Company (USA). Lipid peroxidation was assessed by reac-
tion of malondialdehyde (MDA) with thiobarbituric acid
according to the method of Ohkawa et al. [40]. Total
serum and tissue protein levels were determined by the
Coomassie Blue dye binding method of Bradford [41].
Statistical analysis
Data are expressed as mean +/− SEM. Statistical analysis
was carried out using SPSS V. 21 (IBM). Readings within
each group were compared using the independent sam-
ple test, whereas the readings of the different groups
were compared using One-Way ANOVA: Post hoc mul-
tiple comparisons test. In Post Hoc, equal variances were
assumed by Fisher’s Least Significant Difference, (LSD)
with P < 0.05 being significant.
Results
Effect of AGE on physical measurements
During the 8 weeks of the study, the CN rats more than
doubled in weight (Fig. 1) while the CD rats lost weight
and were over 50 % lighter at 8 weeks compared to the
start of the experiment. In comparison, AGE-D rats recov-
ered in terms of body weight after an initial loss following
STZ injection in a dose–dependent manner with a signifi-
cant increase in weight in AGE300-D and AGE600-D
treatment groups compared to CD rats.
The CD rats greatly increased water (235 ± 3 ml/24 h)
and food (46 ± 2 g/24 h) intake during the experiment
compared to CN rats (40 ± 1 ml/24 h, 30 ± 1 gm/24,
respectively) (Table 1). AGE treatment of diabetic rats
at a dose of 600 mg/kg led to a significantly less food
(34 ± 3 gm/24 h) and water (185 ± 2 ml/24 h) intake
in comparison to CD rats. The two lower doses of
AGE did not have an effect on either food or water
intake.
In comparison, urine output (Table 1) in CD rats was
over 9 times (95 ± 2 ml/24 hrs) the output in CN animals
(10 ± 1 ml/24 hrs). The diabetic animals treated with AGE
at 300 and 600 mg/kg had significantly reduced urine out-
put (89 ± 3 and 87 ± 2 ml/24 hrs, respectively). In com-
parison, the lowest dose of AGE (100 mg/kg) did not have
an effect on urine output (92 ± 1 ml/24 hrs) compared to
CD rats.
Effect of AGE on blood glucose, glycated hemoglobin and
serum insulin
As shown in Fig. 2, blood glucose levels in untreated CD
rats continued to increase throughout the experimental
period, while glucose levels in diabetic rats treated with
300 or 600 mg/kg of AGE decreased significantly. In con-
trast, blood glucose levels in diabetic rats treated with 100
mg/g dose of AGE were not significantly different from
the readings of the CD rats.
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As shown in Fig. 3, induction of diabetes with STZ
resulted in approximately 11-fold reduction in serum in-
sulin level (0.01 ± 0.00 ng/ml) compared to NC rats
(1.15 ± 0.02 ng/ml). AGE treatment of diabetic rats with
doses of 100, 300 or 600 mg/kg resulted in a higher
serum insulin with increases of 9 % (0.09 ± 0.01 ng/ml),
34 % (0.40 ± 0.03 ng/ml) and 64 % (0.75 ± 0.05 ng/ml),
respectively. In contrast and in agreement with serum
glucose levels, GHb was significantly higher in CD rats
(24.9 ± 1.7 %) compared to CN rats (7.8 ± 0.4 %). GHb
levels were significantly decreased by the 300 and 600
mg/kg doses of AGE (19.7 ± 0.8 and 16.0 ± 1.2, respect-
ively), while the 100 mg/kg dose of AGE did not have an
effect on this parameter.
Effect of AGE on serum triglyceride and total cholesterol
Figure 4 shows that serum total cholesterol (3.0 ± 0.1
mM) and triglycerides (1.25 ± 0.10 mM) were signifi-
cantly increased in CD rats compared to CN rats (1.6 ±
0.04 and 0.57 ± 0.03 mM, respectively). The 2 higher
doses of AGE significantly lessened the increase in the
level of cholesterol (1.7 ± 0.1 and 1.8 ± 0.1 mM, re-
spectively) and triglycerides (0.77 ± 0.07 and 0.95 ±
0.09 mM, respectively) compared to CD, while treat-
ment of diabetic rats with the 100 mg/kg dose was not
effective in attenuating the increases in either choles-
terol (2.7 ± 0.08 mM) or triglycerides (1.12 ± 0.03 mM)
in serum.
Effect of AGE on oxidative stress in serum, kidney and liver
Figure 5 illustrates that serum total anti-oxidants, cata-
lase and superoxide dismutase activities (SOD) were sig-
nificantly decreased in CD rats (0.0063 ± 0.0005 mM,
0.0007 ± 2 X 10−6 U/mg protein, 4.89 ± 0.34 U/ml,
respectively) compared to CN rats (0.02 ± 0.01 mM,
0.0023 ± 4 X 10−5 U/mg protein, 7.95 ± 0.62 U/ml,
respectively). Total serum antioxidants and catalase ac-
tivity were significantly increased by treatment of dia-
betic rats with 300 (0.14 ± 0.009 mM, 0.0013 ± 3 x 10−5
U/mg protein, 4.97 ± 0.33 U/ml) and 600 mg/kg of AGE
(0.017 ± 0.01 mM, 0.002 ± 4 X 10−5 U/mg protein,
respectively). Serum SOD activity was only significantly
increased in diabetic rats treated with 600 mg AGE/kg.
The lowest AGE dose (100 mg/kg) had no effect on
serum antioxidant parameters.
In parallel with serum anti-oxidants and catalase, total
kidney and liver anti-oxidants and catalase activity were
significantly lower in CD rats (Figs. 6 and 7). Treatment
with AGE at doses of 300 and 600 mg/kg resulted in
significantly higher kidney and liver anti-oxidants and
catalase activity. In contrast, kidney and liver MDA
a,b
Fig. 1 Dose response of aged garlic extract (AGE) on body weight in diabetic rats. AGE at doses of 100 mg/kg, 300 mg/kg and 600 mg/kg were
administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively. Diabetic control rats (CD) and
normal control rats (CN) were administered normal saline. The animals were weighed before STZ injection (Pre STZ), 1 week after STZ injection
(Post STZ) and at weeks 4 and 8 of the experiment. Weights are plotted as percentiles with the starting weights all standardized to 100 %.
a = significantly decreased compared to normal saline rats; b = significantly increased compared to diabetic control; c = not significantly
different from diabetic control
Table 1 Dose response of aged garlic extract (AGE) on 24 h
urine output, food intake and water intake in diabetic rats






CN 12 10 ± 1 30 ± 1 40 ± 1
CD 12 95 ± 2a 46 ± 2a 235 ± 3a
AGE 600-D 16 87 ± 2a,b 34 ± 3a,b 185 ± 2a,b
AGE 300-D 15 89 ± 3a,b 41 ± 2a,c 225 ± 1a,c
AGE 100-D 15 92 ± 1a, c 41 ± 3a,c 232 ± 1a,c
a = significantly decreased compared to normal saline rats; b = significantly
increased compared todiabetic control; c = not significantly different from
diabetic control
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levels were significantly higher in CD rats compared to
CN rats. AGE-treated rats with the 300 and 600 mg/kg
doses exhibited significantly decreased kidney and liver
MDA levels. Note that the lowest dose of AGE (100 mg/
kg) significantly increased kidney catalase activity and
decreased kidney MDA levels, but had no effect on these
anti-oxidant markers in liver tissues.
Discussion
During the last two decades, considerable research has
been devoted to studying the effects of natural herbs
and spices as alternative forms of treatment for chronic
diseases such as DM. Extensive research has established
that fresh garlic extract and some garlic constituents
have anti-diabetic and anti-oxidant properties. However,
AGE, an over the counter available stable garlic prepar-
ation with known composition, in addition to acceptable
ingestion and side effects attributes, has received little
attention as an anti-diabetic agent. The goal of the
present study was to assess the anti-diabetic and related
anti-oxidant potential of AGE, which is either lacking in
certain aspects or controversially reported in with respect
to other aspects in the literature. Toward that objective
and to define the most active dose or range of doses, a
three incremental-dose–response study of AGE was inves-
tigated in STZ-induced diabetic rats.
Prolonged hyperglycemia in both human conditions and
animal models has been shown to result in the physical
symptoms of diabetes including weight loss, polyphagia,
polydipsia and polyuria [42, 43]. As expected, in the
Fig. 2 Dose response of aged garlic extract (AGE) on blood glucose levels in diabetic rats. AGE at doses of 100 mg/kg, 300 mg/kg and 600 mg/
kg were administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively. Diabetic control rats (CD)
and normal control rats (CN) were administered normal saline. Blood glucose levels were measured before STZ injection (Pre STZ), 1 week after
STZ injection (Post STZ) and at weeks 4 and 8 of the experiment. a = significantly increased compared to normal saline rats; b = significantly








































Fig. 3 Dose response of aged garlic extract (AGE) on serum insulin and RBC GHb in diabetic rats. AGE at doses of 100 mg/kg, 300 mg/kg and
600 mg/kg were administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively. Diabetic control
rats (CD) and normal control rats (CN) were administered normal saline. Serum insulin levels and glycated hemoglobin (GHb) in red blood cells
were measured at the conclusion of the treatment period (8 weeks). a = significantly different compared to normal saline rats; b = significantly
different compared to diabetic control; c = not significantly different from diabetic control
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present study, the STZ-induced CD rats rapidly developed
and maintained these physical symptoms and exhibited
over 50 % weight loss during the 8 week experiment. The
lowest dose of AGE (100 mg/kg) did not have a marked
effect on these parameters, while the AGE-D rats treated
with the 300 or 600 mg/kg doses stabilized their weight
after an initial weight loss, in addition to an improved
polydipsia, polyphagia and polyuria in diabetic rats treated
with 600 mg AGE/kg. Lessening of polyuria in response to
AGE is consistent with the results of Shiju and coworkers
[36] who reported amelioration of polyuria in a 500 mg/kg
oral AGE treated STZ-induced diabetic rats.
In the present study, STZ-injected rats developed a
rapid hyperglycemia and hypoinsulinemia as shown previ-
ously by our group and others [44–46]. Treating diabetic
rats with either 300 or 600 mg/kg dose of AGE signifi-
cantly decreased blood glucose and markedly increased
serum insulin. These results are in contrast with those of
Shiju et al. [36] who did not observe any hypoglycemic ef-
fect of AGE. However, with respect to the anti-glycation
effects, both the current study and that of Shiju et al. [36]
showed that AGE treatment leads to a decrease in GHb.
Thus, these results suggest that AGE may prevent forma-
tion of Amadori products which can lead to protein oxida-
tion. This conclusion is supported by reports that AGE
has potent anti-glycation potential, which may be one of
the mechanisms by which AGE exerts its protective action
in DM [47, 48].
Dyslipidemia, a major symptom and risk factor for the
development of cardiovascular diseases in DM [49, 50] is
characterized by high serum levels of both triglycerides
and cholesterol. Previous studies in both humans and
animals have reported that AGE has a lipid-lowering
property [51]. Similarly, in the present study and as re-
ported by Shiju et al. [36], treatment with all doses of

























Fig. 4 Dose response of aged garlic extract (AGE) on serum total cholesterol and triglycerides in diabetic rats. AGE at doses of 100 mg/kg, 300
mg/kg and 600 mg/kg were administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively.
Diabetic control rats (CD) and normal control rats (CN) were administered normal saline. Serum total cholesterol and triglyceride levels were
measured at the conclusion of the treatment period (8 weeks). a = significantly increased compared to normal saline rats; b = significantly


































































Fig. 5 Dose response of aged garlic extract (AGE) on serum total antioxidants, catalase and SOD in diabetic rats. AGE at doses of 100 mg/kg, 300
mg/kg and 600 mg/kg were administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively.
Diabetic control rats (CD) and normal control rats (CN) were administered normal saline. Serum total antioxidants (mM), catalase activity (U/mg
protein) and SOD activity (U/ml) were determined at the conclusion of the treatment period (8 weeks). a = significantly decreased compared to
normal saline rats; b = significantly increased compared to diabetic control; c = not significantly different from diabetic control
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both serum triglycerides and total cholesterol observed
in the CD rats. Interestingly, treatment of type 2 diabetic
patients with 3000 mg of AGE daily had no effect on
serum cholesterol but did slightly, although not signifi-
cantly, lower serum triglycerides after 3 months of treat-
ment [37]. These observations in the type-2 diabetes
suggest that part of the AGE ameliorative mechanism of
action on body lipids may be mediated at the cellular
level.
Oxidative stress has been implicated as a key con-
tributor to many diabetic complications, including ne-
phropathy [26]. Thus, alleviation of OS is expected to
reverse or at least lessen many of the negative impacts
of DM. A number of studies have investigated the anti-
oxidant potential of AGE and have suggested that AGE
attenuates OS by increasing endogenous anti-oxidant
enzymes, such as catalase and glutathione peroxidase
[22]. In addition, in vitro and in vivo studies have indi-
cated that AGE can reduce both the formation of
superoxide and lipid peroxidation, and thus alleviate
OS [24]. In spite of the established connection between
OS and DM, the anti-oxidant potential of AGE has not
previously been studied in DM. In the current study,
indicators of OS were assessed in serum as well as
kidney and liver tissues of STZ-induced diabetic rats.
As we have previously reported, anti-oxidants were
decreased and OS was increased in serum, liver and
kidneys of this experimental model of CD rats [31, 44].
Treatment with either 300 or 600 mg/kg of AGE sig-













































































Fig. 6 Dose response of aged garlic extract (AGE) on kidney total antioxidants, catalase and MDA in diabetic rats. AGE at doses of 100 mg/kg, 300
mg/kg and 600 mg/kg were administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively.
Diabetic control rats (CD) and normal control rats (CN) were administered normal saline. Total antioxidants (mmole/g tissue), catalase activity (U/mg
protein) and MDA levels (mmole/100 g tissue) were determined in kidney tissue at the conclusion of the treatment period (8 weeks). a = significantly














































































Fig. 7 Dose response of aged garlic extract (AGE) on liver total antioxidants, catalase and MDA in diabetic rats. AGE at doses of 100 mg/kg, 300 mg/kg
and 600 mg/kg were administered IP to diabetic rats for 8 weeks abbreviated as AGE100-D, AGE300-D and AGE600-D, respectively. Diabetic control rats
(CD) and normal control rats (CN) were administered normal saline. Total antioxidants (mmole/g tissue), catalase activity (U/mg protein) and MDA
levels (mmole/100 g tissue) were determined in liver tissue at the conclusion of the treatment period (8 weeks). a = significantly different compared to
normal saline rats; b = significantly different compared to diabetic control; c = not significantly different from diabetic control
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indicated by increased levels of total anti-oxidants and
anti-oxidant enzymes and lowered lipid peroxidation in
liver and kidney tissues. In agreement, Balamash et al.
[37] also reported decreased lipid peroxidation in AGE-
treated diabetic patients.
In an attempt to specify the active components of AGE,
Saravanan et al. [50] investigated the anti-diabetic proper-
ties of SAC, the major garlic-derived component found in
AGE, in STZ-induced diabetic rats. Those investigators
reported that SAC at 100 and 150 mg/kg decreased blood
glucose and GHb and increased serum insulin. Thus, Sar-
avanan and coworkers [52] suggested that SAC may be re-
sponsible for the anti-diabetic effect of AGE. The increase
in insulin concentration induced by AGE may be the
mechanism by which SAC brings about its actions. This
mechanism of action may not be different from that
suggested for fresh garlic. Therefore, we propose that
the anti-diabetic actions of AGE are due to amendment
of the insulin-glucose biochemical pathway. This point
of view is based on the fact that many diabetic symp-
toms are consequences of cellular abnormalities result-
ing from hypoinsulinemia-hyperglycemia. The different
doses of AGE tested gave some indication as to the po-
tency of this natural product preparation, in addition to
suggesting a suitable and tolerable dose that can be
taken as a supplement by diabetics. Although AGE has
many of the same active components as fresh garlic,
the process of aging may have led to attenuation in the
potency of these active components. For that reason, a
larger dose of AGE (600 mg/kg) may be required to in-
duce almost similar actions to those induced by a
slightly lower dose of fresh garlic (500 mg/kg).
Conclusion
In conclusion, the observed attenuating effects of AGE on
the diabetic indicators in STZ-induced diabetic rats sug-
gest that this ready-to-use, fixed concentration, stable
preparation has the potential to be used as a palatable
anti-diabetic agent. Further biochemical and pharmaco-
logical investigations into the insulin-glucose pathway are
necessary to further elucidate the anti-diabetic and con-
nected anti-oxidant mechanism of action of AGE to sup-
port its use as a possible supplementary treatment in DM.
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